Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Regeneron Pharmaceuticals by 8.5% during Q1, now owning 33,252 shares valued at approximately $21.09 million.
• Several other institutional investors have also boosted or acquired stakes in Regeneron, with over 83% of the stock currently held by institutional investors and hedge funds.
• Regeneron reported a quarterly EPS of $12.89, significantly exceeding analyst estimates and a revenue of $3.68 billion, which reflects a 3.6% year-over-year increase.

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 33,252 shares of the biopharmaceutical company's stock after acquiring an additional 2,600 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Regeneron Pharmaceuticals were worth $21,089,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of REGN. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after buying an additional 686 shares during the last quarter. American Assets Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $427,000. Sagespring Wealth Partners LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $382,000. CreativeOne Wealth LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $318,000. Finally, Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $2,192,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the topic of several research analyst reports. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Finally, Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $835.74.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $561.55 on Thursday. The company has a fifty day simple moving average of $540.81 and a two-hundred day simple moving average of $597.08. The company has a market cap of $59.52 billion, a price-to-earnings ratio of 14.15, a price-to-earnings-growth ratio of 1.88 and a beta of 0.33. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.56 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.